Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Background Episodes of depression are the most frequent cause of disability among patients with bipolar disorder. The effectiveness and safety of standard antidepressant agents for depressive episodes associated with bipolar disorder (bipolar depression) have not been well studied. Our study was designed to determine whether adjunctive antidepressant therapy reduces symptoms of bipolar depression without increasing the risk of mania. Methods In this double-blind, placebo-controlled study, we randomly assigned subjects with bipolar depression to receive up to 26 weeks of treatment with a mood stabilizer plus adjunctive antidepressant therapy or a mood stabilizer plus a matching placebo, under conditions generalizable to routine clinical care. A standardized clinical monitoring form adapted from the mood-disorder modules of the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, was used at all follow-up visits. The primary outcome was the percentage of subjects in each treatment group meeting the criterion for a durable recovery (8 consecutive weeks of euthymia). Secondary effectiveness outcomes and rates of treatment-emergent affective switch (a switch to mania or hypomania early in the course of treatment) were also examined. Results Forty-two of the 179 subjects (23.5%) receiving a mood stabilizer plus adjunctive antidepressant therapy had a durable recovery, as did 51 of the 187 subjects (27.3%) receiving a mood stab…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on negative placebo‐controlled data, we do not recommend paroxetine (level 2 negative).245”
In the citing paper
“Antimanic medications reduce depressive symptoms in only one-third of patients (2).”
From Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Trial (2018) · cites this paper as [2]
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
The mini international neuropsychiatric interview
Lecrubier, Y., Sheehan, D., Hergueta, T., & Weiller, E. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80239-9 · Cited by 5,872
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Prevalence and Treatment of Mental Disorders, 1990 to 2003
Kessler, R. C., Demler, O., Frank, R. G., Olfson, M., Pincus, H. A., Walters, E. E., Wang, P., Wells, K. B., & Zaslavsky, A. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa043266 · Cited by 1,910
Extending Indications for Long-Term Pharmacotherapy: Opportunities and Challenges
Kane, J. M. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.1 · Cited by 987
Tohen, M., Vieta, E., Calabrese, J., Ketter, T. A., Sachs, G., Bowden, C., Mitchell, P. B., Centorrino, F., Risser, R., Baker, R. W., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1079 · Cited by 908
Self-citationPerlis, R. H., Ostacher, M. J., Patel, J. K., Marangell, L. B., Zhang, H., Wisniewski, S. R., Ketter, T. A., Miklowitz, D. J., Otto, M. W., Gyulai, L., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.217 · Cited by 689
Self-citationPrevalence and Treatment of Mental Disorders
(2005) · New England Journal of Medicine · doi:10.1056/nejmc051936 · Cited by 650
Research works printed but not linked: 4
- Murray CJ, 1994, Bull World Health Organ, 72, 495
- Sheehan DV, 1998, J Clin Psychiatry, 59, 22
- Sachs GS, 1994, J Clin Psychiatry, 55, 391
- 10.1037/0021-843X.108.4.579 · doi:10.1037/0021-843x.108.4.579 · Paper page
Cited by
Items 301–400 of 935
Characterizing the longitudinal course of symptoms and functioning in bipolar disorder
Mignogna, K. M., & Goes, F. S. (2022) · Psychological Medicine · doi:10.1017/s0033291722001489 · Cited by 32
Bipolar disorder type II revisited
FRANCES, A. J., & Jones, K. D. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2012.01038.x · Cited by 27
Chen, J., Fang, Y., Kemp, D. E., Calabrese, J. R., & Gao, K. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0157-z · Cited by 30
“In contrast, the data from the STEP-BD provide strong evidence that the antidepressants bupropion and paroxetine, when used adjunctively to mood stabilizers, are less likely to increase the risk of TEM in a relatively broad population of patients with BPD [ 43 ].”
ResultSelf-citationReview of Evidence for Use of Antidepressants in Bipolar Depression
McInerney, S. J., & Kennedy, S. H. (2014) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.14r01653 · Cited by 31
Taiwan consensus of pharmacological treatment for bipolar disorder
Bai, Y., Chang, C.-J., Tsai, S., Chen, Y.-C., Hsiao, M., Li, C., Tu, P., Chang, S., Shen, W. W., & Su, T. (2013) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2013.06.013 · Cited by 29
“Nonetheless, the evidence for combination of lithium (or valproate) with antidepressants (sertraline/paroxetine/bupropion) is inconsistent and CE is D in the WFSBP guidelines.(66,67) Due to the Taiwan national insurance database showing that antidepressants are widely prescribed for the depressive episodes in bipolar…”
BackgroundQuetiapine monotherapy for bipolar depression
Thase, M. E. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s1162 · Cited by 30
“…in the largest placebo-controlled study of the role of antidepressants in bipolar depression conducted to date, the addition of paroxetine or bupropion to optimized therapy with mood stabilizers resulted in no added benefi t as compared to therapy with mood stabilizers alone (Sachs et al 2007).”
Self-citationAn Overview of Mood Disorders in the DSM-5
FAWCETT, J. A. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0154-2 · Cited by 27
Keßler, U., Vaaler, A. E., Schoeyen, H. K., Oedegaard, K. J., Bergsholm, P., Andreassen, O. A., Malt, U. F., & Morken, G. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-16 · Cited by 28
“Antidepressants have small if any effect in bipolar depression [6], lithium is not very effective [7], there are a few antipsychotics with effect [8,9], but there are some indications for effect of mood stabilizers [10].”
BackgroundKöhler, S., Gaus, S., & Bschor, T. (2014) · Pharmacopsychiatry · doi:10.1055/s-0033-1364004 · Cited by 29
Depression and Anxiety in Late Life: Diagnostic Insights and Therapeutic Options
Kastenschmidt, E. K., & Kennedy, G. J. (2011) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20266 · Cited by 32
McCain, J. A. (2009) · Europe PMC (PubMed Central) · Cited by 54
Chessick, C. A., PERLICK, D. A., Miklowitz, D. J., Dickinson, L. M., Allen, M. H., Morris, C. D., Gonzalez, J. M., Marangell, L. B., Cosgrove, V. E., Ostacher, M. J., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00765.x · Cited by 26
“Intraclass correlations of physicians’ interrater reliability with gold standard ratings for depression (SUM-D) and mania [continuous symptom subscale for mood elevation (SUM-ME) (30)] ranged from 0.”
BackgroundMethodInfluentialSelf-citationAntidepressant Treatment for Acute Bipolar Depression: An Update
Amit, B. H., & Weizman, A. (2012) · Depression Research and Treatment · doi:10.1155/2012/684725 · Cited by 31
“On the other hand, the two studies showing lack of antidepressant efficacy were based on results of the STEP-BD [29] and EMBOLDEN II trials [14], both of high methodological quality in terms of randomization, control, blinding, and sample size.”
BackgroundMethodInfluentialEffectiveness of lamotrigine in bipolar disorder in a clinical setting
Ketter, T. A., Brooks, J. O., Hoblyn, J. C., Champion, L. M., Nam, J. Y., Culver, J. L., Marsh, W., & Bonner, J. C. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2008.02.007 · Cited by 26
Self-citationFortney, J., Pyne, J., Ward-Jones, S., Bennett, I., Diehl, J., Farris, K. M., Cerimele, J. M., & Curran, G. (2018) · Families, Systems & Health · doi:10.1037/fsh0000357 · Cited by 24
“In the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) medication trial, 35% of patients with BD experienced a 50% reduction by 16 weeks (Sachs et al., 2007).”
MethodA Clinician's Guide to Statistics and Epidemiology in Mental Health: Measuring Truth and Uncertainty
Ghaemi, S. N. (2009) · Cited by 25
Stange, J. P., Sylvia, L. G., Magalhães, P. V. D. S., Miklowitz, D. J., Otto, M. W., Frank, E., Berk, M., Nierenberg, A. A., & Deckersbach, T. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08019 · Cited by 28
Self-citationEffects of adjunctive inflammatory modulation on IL-1β in treatment resistant bipolar depression
Murata, S., Murphy, M. L. M., Hoppensteadt, D., Fareed, J., Welborn, A., & Halaris, A. E. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.01.004 · Cited by 26
Improving Mental Health Treatments Through Comparative Effectiveness Research
Wang, P. S., Ulbricht, C. M., & Schoenbaum, M. (2009) · Health Affairs · doi:10.1377/hlthaff.28.3.783 · Cited by 25
Kelly, M. P., Logue, S. F., Dwyer, J. M., Beyer, C. E., Majchrowski, H., Cai, Z., Liu, Z., Adedoyin, A. B., Rosenzweig-Lipson, S. J., & Comery, T. A. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.03.003 · Cited by 25
“, Dubovsky, 2005), the large STEP-BD study (Systematic Treatment Enhancement Program for Bipolar disorder) has suggested that antidepressants are not efficacious in treating bipolar depression when administered on top of amood stabilizer (Goldberg et al., 2007; Sachs et al., 2007).”
Włodarczyk, A., & Cubała, W. J. (2020) · Medicina · doi:10.3390/medicina56020067 · Cited by 25
State of the Art: Treatment of Bipolar Disorders
Severus, E., Schaaff, N., & Möller, H. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00258.x · Cited by 23
“Out of these three studies the antidepressants were clearly efficacious in one study [26], in the other two studies the antidepressants did not separate from placebo [27,28].”
BackgroundMethodResultInfluentialThe Presentation, Recognition and Management of Bipolar Depression in Primary Care
Cerimele, J. M., Chwastiak, L., Chan, Y.-F., Harrison, D. A., & Unützer, J. (2013) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2545-7 · Cited by 23
Päären, A., von Knorring, A., Olsson, G., von Knorring, L., Bohman, H., & Jonsson, U. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.07.031 · Cited by 24
“However, short-term placebo-controlled trials with antidepressants have not shown higher rates of switch to bipolar disorder than placebo (Ghaemi et al., 2003; Sachs et al., 2007; Amsterdam and Shults, 2010).”
BackgroundThe Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 25
Hu, Y., Zhang, H., Wang, H., Wang, C., Kung, S., & Li, C. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114468 · Cited by 25
Chen, C., Wu, L. S.-H., Huang, M., Kuo, C., & Cheng, A. T. A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12040615 · Cited by 24
Osher, Y., Bersudsky, Y., & Belmaker, R. H. (2010) · Neuropsychobiology · doi:10.1159/000314306 · Cited by 27
Tundo, A., Calabrese, J. R., Proietti, L., & de Filippis, R. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.09.019 · Cited by 22
“This modification was intended to protect against antidepressant-induced switching and supported by an evidence base suggesting that the concomitant use of mood stabilizers decreases switch rates (Boerlin et al., 1998; Henry et al., 2001; Bottlender et al., 2002; Sachs et al., 2007) and mitigate (mostly lithium) AD-em…”
BackgroundSelf-citationAntidepressants in bipolar depression: The clinical debate
Ghaemi, S. N. (2012) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412441035 · Cited by 23
“For instance, the largest (n = 366) welldesigned (most patients received proven mood stabilizers like lithium or anticonvulsants) RCT of bipolar depression was a comparison in the STEP-BD study of bupropion versus paroxetine versus placebo (Sachs et al., 2007).”
BackgroundLorenzo‐Luaces, L., Amsterdam, J. D., Soeller, I., & DeRubeis, R. J. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12557 · Cited by 23
“In the context of concerns over rapid cycling and treatment-induced hypomania, a large placebo-controlled study exploring the efficacy of adjunctive treatments to mood stabilizer monotherapy called into question the efficacy of antidepressants for bipolar I and II depression altogether (22).”
BackgroundAlonzo, A., Aaronson, S. T., Bikson, M., Husain, M. M., Lisanby, S. H., Martin, D. M., McClintock, S. M., McDonald, W. M., O’Reardon, J. P., Esmailpoor, Z., et al. (2016) · Contemporary Clinical Trials · doi:10.1016/j.cct.2016.10.002 · Cited by 22
“Similarly, in the large scale Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) trial of bipolar depression, treatmentwith amood stabiliser led to treatment response in approximately one-third of patients, with one quarter attaining a durable recovery, but without additional benefit from adjuncti…”
ResultShim, I. H., Woo, Y. S., Kim, M.-D., & Bahk, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112406 · Cited by 26
“Contrarily, paroxetine, bupropion, and agomelatine adjunctive therapies did not differ from the placebo or MS treatments [31,36,37].”
BackgroundImplementing clinical guidelines for bipolar disorder
Morriss, R. K. (2008) · Psychology and Psychotherapy Theory Research and Practice · doi:10.1348/147608308x278105 · Cited by 29
A tetrachoric factor analysis validation of mixed depression
Benazzi, F. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.08.005 · Cited by 21
Geddes, J. R., & Miklowitz, D. J. (2014) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.12.2.205 · Cited by 22
Self-citationSerretti, A., Chiesa, A., Calati, R., Fabbri, C., Sentissi, O., Ronchi, D. D., Mendlewicz, J., & Souery, D. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113485143 · Cited by 23
“Finally, taking into account the risk of antidepressant-induced mania and rapid cycling (Nivoli et al., 2011; Sachs et al., 2007), antidepressants should be used only in combination with mood stabilizing agents (Fountoulakis et al., 2012).”
BackgroundSafety and Efficacy of Quetiapine in Bipolar Depression
Bogart, G. T., & Chavez, B. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1m193 · Cited by 26
Rapinesi, C., Kotzalidis, G. D., Ferracuti, S., Girardi, N., Zangen, A., Sani, G., Raccah, R. N., Girardi, P., Pompili, M., & CASALE, A. D. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.02.029 · Cited by 21
An overview of pharmacotherapy for bipolar I disorder
Morsel, A., Morrens, M., & Sabbe, B. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1426746 · Cited by 23
Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder
Cheniaux, E., & Nardi, A. E. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1651291 · Cited by 26
“Paroxetine, bupropion [65], olanzapine/ fluoxetine combination [58,59], fluoxetine [56], venlafaxine [69,76] and agomelatine [75] were the therapeutic options evaluated.”
BackgroundResultInfluentialWang, D., & Osser, D. N. (2019) · Bipolar Disorders · doi:10.1111/bdi.12860 · Cited by 23
Treatment-refractory bipolar disorder: classification to aid in clinical management
Gajwani, P. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903064170 · Cited by 22
“Contrasting results were reported with the recent STEP-BD (Systemic Treatment Enhancement Program – Bipolar Disorder) program [9].”
BackgroundResultGoldberg, J. F., Calabrese, J. R., Saville, B. R., Frye, M. A., Ketter, T. A., Suppes, T. M., Post, R. M., & Goodwin, F. K. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04381 · Cited by 22
Self-citationClass effect of pharmacotherapy in bipolar disorder: fact or misbelief?
Fountoulakis, K. Ν., Gonda, X., Vieta, E., & Rihmer, Z. (2011) · Annals of General Psychiatry · doi:10.1186/1744-859x-10-8 · Cited by 23
“depression are equivocal [35,96-98,103,115,125-131].”
Effectiveness as an outcome measure for treatment trials in psychiatry
Fleischhacker, W. W., & Goodwin, G. M. (2009) · World Psychiatry · doi:10.1002/j.2051-5545.2009.tb00200.x · Cited by 21
“The findings were negative, with no evidence for remission (or for switch to mania) occurring preferentially in the antidepressant arm (25).”
BackgroundA systematic review of the evidence for the treatment of acute depression in bipolar I disorder
Cerullo, M. A., & Strakowski, S. M. (2013) · CNS Spectrums · doi:10.1017/s1092852913000102 · Cited by 21
“Sachs et al.(40) studied paroxetine and buproprion SR as adjunctive treatments in 366 participants taking a mood stabilizer or atypical antipsychotic.”
BackgroundMardani, P., Hassanvandi, S., Dadashi, M., Zolghadriha, A., Javadani, H., & Mousavi, S. E. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03592-6 · Cited by 23
Jeong, J., Bahk, W., Woo, Y. S., Yoon, B.-H., Lee, J. G., Kim, W., Sohn, I., Park, S., Shim, S.-H., Seo, J. S., et al. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2023.21.1.32 · Cited by 21
“such as affective switching, higher suicide risk, and increased risk of development of mixed states/rapid cycling, and a limited evidence for their efficacy [55,56].”
Bipolar depression: clinically missed, pharmacologically mismanaged
Lloyd, L. C., Giaroli, G., Taylor, D. M., & Tracy, D. K. (2011) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125311420752 · Cited by 21
“Introduction Bipolar affective disorders (BPADs) are complex mental illnesses that are frequently severe and chronic, and constitute a significant cause of disability and premature death [Nierenberg, 2008; Belmaker, 2007; Sachs et al. 2007; Bauer and Pfennig, 2005; Calabrese et al. 2005; Frye, 2011; Judd et al. 2003,…”
BackgroundMansell, W., Tai, S., Clark, A., Akgonul, S., Dunn, G., Davies, L., Law, H., Morriss, R., Tinning, N., & Morrison, A. P. (2014) · Trials · doi:10.1186/1745-6215-15-405 · Cited by 20
“At present, antidepressant treatment is relatively ineffective for these individuals [7].”
BackgroundGrover, S., Avasthi, A., Chakravarty, R. K., Dan, A., Chakraborty, K., Neogi, R., Desouza, A., Nayak, O., Praharaj, S. K., Menon, V., et al. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102549 · Cited by 20
The Contemporary Face of Bipolar Illness:Complex Diagnostic and Therapeutic Challenges
Fountoulakis, K. Ν. (2008) · CNS Spectrums · doi:10.1017/s1092852900013894 · Cited by 23
Arvilommi, P., Suominen, K. H., Mantere, O., Leppämäki, S., Valtonen, H. M., & Isometsä, E. T. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.05.005 · Cited by 19
Is Monotherapy as Good as Polypharmacy in Long—Term Treatment of Bipolar Disorder?
Alda, M., & Yatham, L. N. (2009) · The Canadian Journal of Psychiatry · doi:10.1177/070674370905401101 · Cited by 20
Byatt, N., Cox, L., Simas, T. A. M., Kini, N., Biebel, K., Sankaran, P., Swartz, H. A., & Weinreb, L. (2018) · Archives of Women s Mental Health · doi:10.1007/s00737-018-0825-2 · Cited by 22
Goldberg, J. F. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20190008 · Cited by 20
Kelly, T. (2019) · Bipolar Disorders · doi:10.1111/bdi.12753 · Cited by 21
Lithium as a disease-modifying drug for bipolar disorder
Post, R. M., Li, V. W., Berk, M., & Yatham, L. N. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00097-5 · Cited by 24
Antidepressants in Type II Versus Type I Bipolar Depression: A Randomized Discontinuation Trial
Vöhringer, P. A., Ostacher, M. J., El‐Mallakh, R. S., Holtzman, N. S., Thommi, S. B., Whitham, E. A., Sullivan, M. C., Baldassano, C. F., Goodwin, F. K., Baldessarini, R. J., et al. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000384 · Cited by 19
Self-citationRohde, C., Østergaard, S. D., & Jefsen, O. H. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230477 · Cited by 21
Characteristics of bipolar disorder patients given antidepressants
Lorenzo, L. S., Vázquez, G. H., Zaratiegui, R. M., Tondo, L., & Baldessarini, R. J. (2012) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2253 · Cited by 18
“However, such effects remain unproved (Sachs et al., 2007; Ghaemi et al., 2008; Altshuler et al., 2009; Baldessarini et al., 2010; Frye et al., 2011).”
MAOIs – does the evidence warrant their resurrection?
Menkes, D. B., Bosanac, P., & Castle, D. J. (2016) · Australasian Psychiatry · doi:10.1177/1039856216634824 · Cited by 18
Kauer‐Sant’Anna, M., Frey, B. N., Fijtman, A., Souza, A. C. M. L., Dargél, A., Pfaffenseller, B., Wollenhaupt-Aguiar, B., Gazalle, F. K., Colpo, G. D., Passos, I. C., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119826602 · Cited by 19
“The use of antidepressants as adjunctive treatments to mood stabilizers is helpful in only a quarter of patients with bipolar depression (Sachs et al., 2007).”
BackgroundBridging Bench and Practice: Translational Research for Schizophrenia and Other Psychotic Disorders
Wang, P. S., HEINSSEN, R. K., Oliveri, M., Wagner, A., & Goodman, W. K. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.170 · Cited by 19
El‐Mallakh, R. S., Elmaadawi, A. Z., Loganathan, M. A., Lohano, K., & Gao, Y. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.07.2172 · Cited by 20
Wu, F., Laber, E. B., Lipkovich, I. A., & Severus, E. (2015) · International Journal of Bipolar Disorders · doi:10.1186/s40345-014-0018-5 · Cited by 23
“The study on which our analyses are based was approved by the institutional review board at each study site and was overseen by a data and safety monitoring board (for more details, see http://www.ncbi.nlm.nih.gov/pubmed/ 17392295).”
BackgroundMethodInfluentialAre guidelines in need of CPR? The development of clinical practice recommendations (CPR)
Malhi, G. S., & Adams, D. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01381.x · Cited by 20
“A good example of this dissonance is the difference in the efficacy evidence between real-world trials, such as the STAR*D (8) and STEP-BD (9) studies, and randomised controlled trials (RCTs) conducted for regulatory purposes (10).”
BackgroundEffectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation
Rodrigues, N. B., Siegel, A., Lipsitz, O., Cha, D. S., Gill, H., Nasri, F., Simonson, K., Shekotikhina, M., Lee, Y., Subramaniapillai, M., et al. (2022) · CNS Spectrums · doi:10.1017/s1092852920002187 · Cited by 17
“Evenhigher rates of TRDare observed inBD, as indicated by the Systematic Treatment Enhancement Program for Bipolar Disorder Study.(3) As such, low remission rates and inadequate response to current treatment options are a major unmet need within mood disorder populations.”
Korean Medication Algorithm Project for Bipolar Disorder 2022, Fifth Revision: An Executive Summary
Woo, Y. S., Bahk, W., Jeong, J., Lee, J. G., Kim, W., Sohn, I., Park, S., Shim, S.-H., Seo, J. S., Choo, I. H., et al. (2022) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2022.20.4.747 · Cited by 20
“These changes in the recommendations presented in the KMAP-BP over time reflect the controversy and debate surrounding the use of ADs for bipolar depression due to potentially increased risk of harm, such as affective switching, higher suicide risk, and increased risk of development of mixed states, and a limited evid…”
MethodTada, M., Uchida, H., Mizushima, J., Suzuki, T., Mimura, M., & Nio, S. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.06.015 · Cited by 20
“Durable recovery, which was defined as euthymia: presence of 2 unequivocally present affective symptoms listed in the Clinical Monitoring Form for at least eight consecutive weeks (Sachs et al., 2007), was adopted as the primary outcome in the present study.”
BackgroundMethodInfluentialCorrelates of Treatment Response in Depressed Older Adults With Bipolar Disorder
Gildengers, A. G., Tatsuoka, C. M., Bialko, C. S., Cassidy, K. A., Jurdi, R. K. A., Gyulai, L., Mulsant, B. H., Young, R. C., & Sajatovic, M. (2012) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988712436685 · Cited by 20
Self-citationManagement of obsessive-compulsive disorder comorbid with bipolar disorder
Kazhungil, F., & Mohandas, E. (2016) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.192001 · Cited by 19
“There are no studies specifically focusing on patients with BD and a specific comorbid anxiety disorder.[90-92] Although there no controlled trials, ADs are commonly prescribed to BD patients for treating anxiety symptoms.”
BackgroundFornaro, M., Stubbs, B., Berardis, D. D., Iasevoli, F., Solmi, M., Veronese, N., Carano, A., Perna, G., & de Bartolomeis, A. (2016) · Clinical Practice and Epidemiology in Mental Health · doi:10.2174/1745017901612010142 · Cited by 17
“In this regard, although adjunctive antidepressant treatment for established mood stabilizers has been excluded to be associated with increased risk for treatment-emergent switch (or antidepressant-efficacy) in BD [50], any conclusive statement about the actual clinical predictive value of lifetime antidepressant expo…”
ResultIatrogenia y prevención cuaternaria en salud mental
Lobo, A. O., & Rojo, V. (2011) · Revista Española de Salud Pública · doi:10.1590/s1135-57272011000600002 · Cited by 48
Adjunctive Behavioral Activation for the Treatment of Bipolar Depression: A Proof of Concept Trial
Weinstock, L. M., Melvin, C., MUNROE, M. K., & Miller, I. W. (2016) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000142 · Cited by 18
Antosik-Wójcińska, A. Z., Stefanowski, B., & Święcicki, Ł. (2015) · Psychiatria Polska · doi:10.12740/pp/37914 · Cited by 22
“[21] Phase change risk assessment after adding AD to mood stabilizer compared to placebo 179 patients receiving AD + mood stabilizer,”
MethodResultInfluentialRisperidone- and Aripiprazole-Induced Leukopenia: A Case Report
Qureshi, S. U., & Rubin, E. (2008) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v10n0612c · Cited by 17
Born, C., Seitz, N.-N., Grunze, H., Vieta, E., Dittmann, S., Seemüller, F., & Amann, B. L. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01412.x · Cited by 18
“Paulsson, personal communication) and paroxetine or bupropion in combination with a mood stabilizer (34), and long-term data of the SFBN are more supportive of a mood stabilizing effect in acute antidepressant responders maintained on this medication (35).”
BackgroundCurrent issues: women and bipolar disorder
Marangell, L. B. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.2/lbmarangell · Cited by 17
“Recent randomized evidence suggests that antidepressants added to adequate doses of antimanic medications do not improve outcomes in bipolar depression.(15) Taken together, at this juncture, when a woman with bipolar disorder presents with depression or rapid cycling, it appears prudent to optimize mood stabilizers, c…”
Self-citationBirnbaum, H. G., Ben-Hamadi, R., Kelley, D., Hsieh, M., Seal, B. S., Kantor, E., Crémieux, P., & Greenberg, P. E. (2010) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0b013e3181cb5b10 · Cited by 22
Mixed Depression: The Importance of Rediscovering Subtypes of Mixed Mood States
Schneck, C. D. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08111669 · Cited by 17
“Studies have demonstrated that the addition of antidepressants may provide no more benefit than treatment with mood stabilizers alone (9), may worsen manic symptoms in patients with mixed depressive symptoms (10), and may significantly increase the frequency of suicidal ideation (11).”
BackgroundAntidepressants and Bipolar Disorder: The Plot Thickens
Gottlieb, N., & Young, A. H. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240411 · Cited by 22
Advances in the psychopharmacotherapy of bipolar disorder type I
Sleem, A., & El‐Mallakh, R. S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1893306 · Cited by 16
“Adding a serotonin-reuptake inhibiting antidepressant, such as fluoxetine, to an antipsychotic, such as olanzapine, is associated with a small effect size of improvement, with no demonstrated efficacy of olanzapine alone [214], but there is evidence showing that this does not happen when an antidepressant is added to…”
BackgroundMethodInfluentialBobo, W. V., EPSTEIN, R. A., & Shelton, R. C. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1082 · Cited by 16
Diagnosis and Management of Bipolar Disorder in Primary Care
Brenner, C. J., & Shyn, S. I. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.06.004 · Cited by 24
“findings highlight the need for wider implementation of evidence-based strategies, particularly in light of the general lack of appreciable benefit with standard antidepressants in the treatment of BD.(30)”
BackgroundInfluentialThe preclinical discovery and development of quetiapine for the treatment of mania and depression
de Miranda, A. S., Moreira, F. A., & Teixeira, A. L. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1304378 · Cited by 18
“a combination of antidepressant and mood stabilizer [47].”
BackgroundAgmatine as a potential therapeutic intervention in bipolar depression: the preclinical landscape
Watts, D., Pfaffenseller, B., Wollenhaupt-Aguiar, B., Géa, L. P., Cardoso, T. D. A., & Kapczinski, F. P. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1581764 · Cited by 20
“use of antidepressants with mood stabilizers, are only helpful in a quarter of patients with bipolar depression [18].”
MethodAnsari, A., & Osser, D. N. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673220903523524 · Cited by 20
Bupropion extended-release for depressive disorders
Jefferson, J. W. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.5.715 · Cited by 18
A retrospective analysis of bipolar depression treated with transcranial magnetic stimulation
Goldwaser, E. L., Daddario, K., & Aaronson, S. T. (2020) · Brain and Behavior · doi:10.1002/brb3.1805 · Cited by 15
“…provides no improved outcome but may, on the contrary, carry the risk of precipitating or supporting a mixed or manic episode, bringing to light not only a question of benefit, but even harm and safety in their provision (El-Mallakh et al., 2015; Goldberg et al., 2007; Sachs et al., 2007).”
BackgroundNassir Ghaemi, S., Vohringer, P. A., & Whitham, E. A. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12059 · Cited by 15
“In a randomized double-blind placebo controlled trial, they were found to be equivalent to placebo (15).”
BackgroundJefsen, O. H., Rohde, C., & Østergaard, S. D. (2023) · Bipolar Disorders · doi:10.1111/bdi.13353 · Cited by 19
Treatment outcomes of acute bipolar depressive episode with psychosis
Caldieraro, M. A., Dufour, S. C., Sylvia, L. G., Gao, K., Ketter, T. A., Bobo, W. V., Walsh, S. L., JANOS, J. A., Tohen, M. F., Reilly-Harrington, N. A., et al. (2018) · Depression and Anxiety · doi:10.1002/da.22716 · Cited by 15
“The overall remission rates were consistent with other pragmatic clinical trials on outpatients with BD (Nierenberg et al., 2013; Sachs et al., 2007).”
ResultSelf-citationCurrent and Emerging Therapies for the Management of Bipolar Disorders
El‐Mallakh, R. S., Elmaadawi, A. Z., Gao, Y., Lohano, K., & Roberts, R. J. (2011) · Journal of Central Nervous System Disease · doi:10.4137/jcnsd.s4441 · Cited by 15
Overview of Antidepressant Treatment of Bipolar Depression
Vázquez, G. H., Tondo, L., Undurraga, J. P., & Baldessarini, R. J. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.130119 · Cited by 15
Management of Bipolar II Disorder
Wong, M. M. C. (2011) · Indian Journal of Psychological Medicine · doi:10.4103/0253-7176.85391 · Cited by 17
“The STEP-BP study,[68] comparing adjunctive antidepressants (bupropion or paroxetine) plus lithium or valproate and lithium or valproate alone, for up to 26 weeks, included 114 patients with BP II.”
Different Neural Responses to a Moral Valence Decision Task in Unipolar and Bipolar Depression
Radaelli, D., Dallaspezia, S., Poletti, S., Smeraldi, E., Falini, A., Colombo, C., & Benedetti, F. (2013) · ISRN Psychiatry · doi:10.1155/2013/568617 · Cited by 16
The pharmacological treatment of bipolar disorder in primary care
Malhi, G. S., Adams, D., & Berk, M. (2010) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2010.tb03894.x · Cited by 21
Goldberg, J. F., Ng‐Mak, D., SIU, C. O., Chuang, C., Rajagopalan, K., & Loebel, A. D. (2017) · CNS Spectrums · doi:10.1017/s1092852917000025 · Cited by 15
Metadata
- Authors
- Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., Ketter, T. A., Patel, J., Hauser, P., Rapport, D., Martinez, J. M., Allen, M. H., Miklowitz, D. J., Otto, M. W., Dennehy, E. B., & Thase, M. E.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- University Hospitals Cleveland Medical Center (US)
- Baylor College of Medicine (US)
- University of Pittsburgh (US)
- University of Pennsylvania (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of Oklahoma (US)
- Stanford Medicine (US)
- University of Massachusetts Chan Medical School (US)
- University of Toledo (US)
- University of Colorado Boulder (US)
- Boston University (US)
- Purdue University West Lafayette (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-26
- Volume
- 356
- Issue
- 17
- Pages
- 1711-1722
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2166423384
- Semantic Scholar
- c224a40d0ffd6471e7b72b38060d169ba1cdec34
- Cited by
- 937
- References
- 27
- Citations by year
- 2026: 16 · 2025: 16 · 2024: 33 · 2023: 17 · 2022: 15 · 2021: 68 · 2020: 33 · 2019: 29 · 2018: 36 · 2017: 28 · 2016: 53 · 2015: 47 · 2014: 51 · 2013: 52 · 2012: 61
- FWCI
- 56.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (n01mh80001-12-0-0)
- National Institute of Mental Health (N01-MH80001)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Keywords
- bipolar depression, adjunctive antidepressant therapy, mood stabilizers, euthymia, bipolar disorder, antidepressant safety
- MeSH terms
- Adult, Bipolar Disorder, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Bupropion, Treatment Outcome, Paroxetine, Antidepressive Agents, Second-Generation, Antimanic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.